AstraZeneca plans to delist from Nasdaq and move to the NYSE, while its breast cancer drug Enhertu enters European regulatory ...

AstraZeneca (NASDAQ:AZN) has announced it will shift its US listing from Nasdaq to the New York Stock Exchange, delisting its ...

The company says the proposal will create space for hundreds of its staff to work at the campus.

Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth-quarter 2025 investor letter.

AstraZeneca is relying on several upcoming products to help hit its target of $80 billion in revenue by 2030, including drugs ...

London: British pharmaceutical giant AstraZeneca on Tuesday said trading of its shares on the New York Stock Exchange will start from February, in ...

AstraZeneca (NASDAQ:AZN) is one of the best future stocks to buy for the long term. On January 6, Barclays analyst James ...

AstraZeneca PLC aims for $80 billion in revenue by 2030, driven by strong growth in oncology, biopharmaceuticals, and rare diseases, despite recent share price declines. The company's weight ...

Global pharmaceutical manufacturer and biotech company AstraZeneca plans to construct a multibillion dollar manufacturing center focused on chronic diseases in Virginia within the next five years, it ...

Astrazeneca (AZN) closed at $96.34 in the latest trading session, marking a +1.94% move from the prior day. The stock ...

Add Yahoo as a preferred source to see more of our stories on Google. We reached out to numerous Latin language experts, all of whom confirmed the same thing: The above translation is wrong and "a ...